No kidding about the Amarin investors. The FDA shot down what might be a tremendous product.
I can't help but wonder what would have happened had AMRN aligned itself with or had sold itself to a big pharma. Did they get burnt here being the little guy? Did GSK (Glaxo) have any role in this? Glaxo had a lot at stake here, as AMRN's drug would have cut into their current market-leading drug. And there's a lot of talk that one of GSK's board members is on the FDA ADCOM committee....hmmm...makes you wonder sometimes.